Introduction
Calcium pyrophosphate deposition disease (CPPD), a crystal arthropathy affecting synovial and periarticular tissues, presents a spectrum of clinical scenarios from asymptomatic conditions to acute and chronic inflammatory arthritis. Understanding its varied presentations is crucial for accurate diagnosis, especially when differentiating it from other rheumatologic conditions. Chondrocalcinosis, the radiological hallmark of CPPD characterized by intraarticular fibrocartilage calcification, often plays a pivotal role in diagnosis, yet its differential diagnosis is complex and requires careful consideration. This article delves into the differential diagnosis of chondrocalcinosis, particularly in the context of CPPD, aiming to provide a comprehensive guide for healthcare professionals.
Etiology of CPPD and Chondrocalcinosis
The underlying cause of calcium pyrophosphate deposition disease is thought to be an imbalance in pyrophosphate production and pyrophosphatases within cartilage. This imbalance leads to pyrophosphate accumulation, which then combines with calcium to form calcium pyrophosphate dihydrate (CPPD) crystals in the synovium and surrounding tissues. Several associated comorbidities can predispose individuals to CPPD. Hyperparathyroidism, gout, osteoarthritis, rheumatoid arthritis, and hemochromatosis are strongly linked with CPPD. Other conditions like osteoporosis, hypomagnesemia, chronic kidney disease, and calcium supplementation are also noted comorbidities. The deposition of CPPD crystals triggers an immune response, leading to inflammation and potential tissue damage.
Epidemiology of Chondrocalcinosis
The prevalence of chondrocalcinosis increases significantly with age. Acute CPPD arthritis predominantly affects individuals over 65 years of age, with a notable percentage of cases occurring in those over 85. Epidemiological studies indicate that radiographic chondrocalcinosis is present in a substantial portion of the general population, with crude prevalence rates around 4%. While CPPD is less common in individuals under 60, the likelihood of chondrocalcinosis and associated CPPD increases markedly in older age groups.
Clinical Presentation and Diagnostic Challenges
Patients with acute calcium pyrophosphate arthritis typically present with symptoms mimicking acute gout, including joint edema, erythema, and tenderness. Knee joints are most commonly affected, but other weight-bearing joints like hips and shoulders can also be involved. A subset of patients develops chronic CPP arthritis, characterized by fluctuating episodes of inflammatory arthritis affecting multiple joints, including non-weight-bearing joints such as wrists and metacarpophalangeal (MCP) joints. This chronic presentation can closely resemble rheumatoid arthritis, posing diagnostic challenges. In elderly patients presenting with acute degenerative arthritis in weight-bearing joints, especially after trauma, crystal deposition disease should be considered.
Evaluation and Diagnostic Modalities
The diagnostic approach for suspected CPPD involves a combination of clinical evaluation, synovial fluid analysis, and imaging. Arthrocentesis and synovial fluid analysis are crucial for definitive diagnosis. Polarized microscopy of synovial fluid aspirate can reveal rhomboid-shaped CPPD crystals exhibiting positive birefringence.
Radiography is essential for identifying chondrocalcinosis, the characteristic calcification within joint cartilage. However, it’s important to note that the absence of radiographic chondrocalcinosis does not exclude CPPD. Ultrasound (US) can detect early cartilage abnormalities and chondrocalcinosis. Magnetic resonance imaging (MRI), particularly gradient-echo sequences, is valuable in assessing the burden of CPPD crystal deposition in joint cartilage.
Chondrocalcinosis Differential Diagnosis: Key Considerations
The differential diagnosis of chondrocalcinosis is broad and encompasses various conditions that can present with joint pain, inflammation, and radiographic abnormalities. It is essential to differentiate CPPD from other arthropathies that may mimic its clinical and radiological features. Here are key differential diagnoses to consider:
1. Gout
Gout, another crystal arthropathy, is caused by monosodium urate crystal deposition. Like CPPD, gout can present with acute inflammatory arthritis, often affecting the big toe (podagra).
Distinguishing features:
- Crystal Morphology: Gout crystals are needle-shaped and exhibit negative birefringence under polarized light microscopy, unlike rhomboid-shaped, positively birefringent CPPD crystals.
- Joint Distribution: While both can affect the knee, gout is more typical in the first metatarsophalangeal joint, while CPPD is more common in the knee, wrist, and shoulder.
- Radiography: Gout can cause erosions and tophi, which are different from the cartilage calcification seen in chondrocalcinosis. However, gout does not directly cause chondrocalcinosis. Chondrocalcinosis, while sometimes co-existing with gout, is not a feature of gout itself.
2. Rheumatoid Arthritis (RA)
Chronic CPPD arthritis, or pseudo-rheumatoid arthritis, can closely resemble rheumatoid arthritis, particularly in its polyarticular presentation affecting wrists and MCP joints.
Distinguishing features:
- Synovial Fluid Analysis: Crucially differentiates the two. CPPD is diagnosed by identifying CPPD crystals in synovial fluid, which are absent in RA. RA synovial fluid shows inflammatory changes but no crystals.
- Radiography: RA typically shows erosions and joint space narrowing, while CPPD shows chondrocalcinosis. While both conditions can cause joint damage, the underlying radiographic findings are distinct.
- Serology: Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies are often positive in RA and negative in CPPD.
- Clinical Course: While both can be chronic, the pattern of flares and joint involvement might differ. CPPD flares can be more intermittent, while RA is often characterized by persistent synovitis.
3. Ankylosing Spondylitis (AS)
In rare cases, CPPD can involve the spine, mimicking ankylosing spondylitis, especially when causing spinal stiffness and bony ankylosis.
Distinguishing features:
- Joint Distribution: AS primarily affects the axial skeleton (spine and sacroiliac joints), while CPPD more commonly affects peripheral joints, although spinal involvement can occur.
- Radiography: AS shows sacroiliitis, syndesmophytes, and squaring of vertebrae. CPPD in the spine might show ligament calcification and facet joint chondrocalcinosis, but the overall radiographic pattern differs.
- HLA-B27: Often positive in AS and negative in CPPD.
- Clinical Features: AS typically presents with inflammatory back pain that improves with exercise and worsens with rest, often starting in younger individuals. CPPD is more common in older adults and may not have the same inflammatory back pain pattern.
4. Erosive Osteoarthritis (EOA)
Erosive osteoarthritis, particularly affecting the interphalangeal joints of the hands, can sometimes be confused with CPPD, especially if chondrocalcinosis is present in these joints.
Distinguishing features:
- Joint Distribution: EOA primarily affects distal and proximal interphalangeal (DIP and PIP) joints of the hands, while CPPD can affect various joints, including knees, wrists, and MCPs.
- Radiography: EOA shows erosions, joint space narrowing, and osteophytes. Chondrocalcinosis can coexist in OA, but EOA is defined by its erosive nature. The presence of prominent chondrocalcinosis in unusual locations might suggest CPPD even in the setting of OA.
- Synovial Fluid Analysis: While both can have non-inflammatory synovial fluid in chronic stages, acute flares of CPPD will show CPPD crystals, which are absent in EOA.
5. Septic Arthritis
Acute CPPD arthritis can mimic septic arthritis due to the presence of joint inflammation and potential fever.
Distinguishing features:
- Synovial Fluid Analysis: Crucial for differentiation. Septic arthritis shows high white blood cell count (predominantly neutrophils) and bacteria on Gram stain and culture. CPPD shows CPPD crystals and a lower white blood cell count (though still elevated).
- Clinical Context: Risk factors for septic arthritis (e.g., intravenous drug use, immunocompromised state, recent joint surgery) should raise suspicion for infection.
6. Other Crystal Arthropathies
Besides gout, other less common crystal deposition diseases, such as basic calcium phosphate (BCP) crystal deposition disease (e.g., Milwaukee shoulder syndrome), can also present with joint symptoms and may need to be considered in the differential diagnosis. BCP crystals are small, non-birefringent, and require special stains or electron microscopy for identification, differentiating them from CPPD crystals.
Treatment and Management Implications
Accurate differential diagnosis is critical as treatment strategies differ significantly among these conditions. CPPD management focuses on reducing inflammation during acute flares and managing underlying metabolic conditions. Treatment options include joint aspiration and intra-articular glucocorticoids, systemic NSAIDs, colchicine, and systemic glucocorticoids. Unlike gout, there is no specific therapy to dissolve CPPD crystals. Management of rheumatoid arthritis and ankylosing spondylitis involves disease-modifying antirheumatic drugs (DMARDs), while osteoarthritis management is primarily symptomatic. Septic arthritis requires urgent antibiotic therapy. Therefore, distinguishing CPPD from these conditions is paramount for appropriate patient care.
Prognosis and Long-Term Considerations
The prognosis of acute CPPD arthritis is generally favorable, with inflammation typically resolving within days to weeks. However, chronic CPPD arthritis can have a more variable and prolonged course, potentially leading to joint damage over time. Complications of CPPD can include joint degradation and, rarely, spinal cord compression. Patient education regarding predisposing factors and the importance of managing underlying metabolic conditions is crucial for long-term management and deterrence of acute flares.
Enhancing Healthcare Team Outcomes
Effective diagnosis and management of CPPD and chondrocalcinosis require a collaborative interprofessional team approach. Rheumatologists, radiologists, primary care physicians, and other healthcare professionals play vital roles in recognizing, diagnosing, and managing this condition. Utilizing high-resolution ultrasound and other advanced imaging modalities, along with careful synovial fluid analysis, enhances diagnostic accuracy. Improved communication and coordination among healthcare team members are essential to optimize patient outcomes and ensure appropriate management strategies are implemented, particularly in differentiating chondrocalcinosis and CPPD from its differential diagnoses.
Review Questions
1. Which of the following crystal shapes and birefringence characteristics is consistent with CPPD crystals?
a) Needle-shaped, negative birefringence
b) Rhomboid-shaped, negative birefringence
c) Needle-shaped, positive birefringence
d) Rhomboid-shaped, positive birefringence
2. Chondrocalcinosis is a characteristic radiological finding in:
a) Gout
b) Rheumatoid Arthritis
c) Calcium Pyrophosphate Deposition Disease (CPPD)
d) Ankylosing Spondylitis
3. Synovial fluid analysis in CPPD typically reveals:
a) Monosodium urate crystals
b) CPPD crystals
c) Bacteria
d) High rheumatoid factor
4. Which condition is most likely to mimic chronic CPPD arthritis (pseudo-rheumatoid arthritis)?
a) Gout
b) Rheumatoid Arthritis
c) Ankylosing Spondylitis
d) Erosive Osteoarthritis
Answer Key: 1: d, 2: c, 3: b, 4: b
Figure: CPP and Urate Crystals
Image courtesy of S Bhimji MD
References
1.Rosales-Alexander JL, Balsalobre Aznar J, Magro-Checa C. Calcium pyrophosphate crystal deposition disease: diagnosis and treatment. Open Access Rheumatol. 2014;6:39-47. [PMC free article: PMC5045115] [PubMed: 27790033]
2.Bencardino JT, Hassankhani A. Calcium pyrophosphate dihydrate crystal deposition disease. Semin Musculoskelet Radiol. 2003 Sep;7(3):175-85. [PubMed: 14593559]
3.Abhishek A. Calcium pyrophosphate deposition disease: a review of epidemiologic findings. Curr Opin Rheumatol. 2016 Mar;28(2):133-9. [PubMed: 26626724]
4.Higgins PA. Gout and pseudogout. JAAPA. 2016 Mar;29(3):50-2. [PubMed: 26914781]
5.Kleiber Balderrama C, Rosenthal AK, Lans D, Singh JA, Bartels CM. Calcium Pyrophosphate Deposition Disease and Associated Medical Comorbidities: A National Cross-Sectional Study of US Veterans. Arthritis Care Res (Hoboken). 2017 Sep;69(9):1400-1406. [PMC free article: PMC5472491] [PubMed: 27898996]
6.Galozzi P, Oliviero F, Frallonardo P, Favero M, Hoxha A, Scanu A, Lorenzin M, Ortolan A, Punzi L, Ramonda R. The prevalence of monosodium urate and calcium pyrophosphate crystals in synovial fluid from wrist and finger joints. Rheumatol Int. 2016 Mar;36(3):443-6. [PubMed: 26440935]
7.Gerster JC, Varisco PA, Kern J, Dudler J, So AK. CPPD crystal deposition disease in patients with rheumatoid arthritis. Clin Rheumatol. 2006 Jul;25(4):468-9. [PubMed: 16365684]
8.Theiler G, Quehenberger F, Rainer F, Neubauer M, Stettin M, Robier C. The detection of calcium pyrophosphate crystals in the synovial fluid of patients with rheumatoid arthritis using the cytospin technique: prevalence and clinical correlation. Rheumatol Int. 2014 Jan;34(1):137-9. [PubMed: 23269567]
9.Tausche AK, Aringer M. [Chondrocalcinosis due to calcium pyrophosphate deposition (CPPD). From incidental radiographic findings to CPPD crystal arthritis]. Z Rheumatol. 2014 May;73(4):349-57; quiz 358-9. [PubMed: 24811359]
10.Neame RL, Carr AJ, Muir K, Doherty M. UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte. Ann Rheum Dis. 2003 Jun;62(6):513-8. [PMC free article: PMC1754579] [PubMed: 12759286]
11.Yamamura M. Acute CPP Crystal Arthritis Causing Carpal Tunnel Syndrome. Intern Med. 2018 Oct 01;57(19):2767-2768. [PMC free article: PMC6207825] [PubMed: 29780133]
12.MUNDAY MC. PSEUDOGOUT. Br Med J. 1964 Oct 10;2(5414):889-90. [PMC free article: PMC1816901] [PubMed: 14185646]
13.Becker JA, Daily JP, Pohlgeers KM. Acute Monoarthritis: Diagnosis in Adults. Am Fam Physician. 2016 Nov 15;94(10):810-816. [PubMed: 27929277]
14.Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, Leeb BF, Perez-Ruiz F, Pimentao J, Punzi L, Richette P, Sivera F, Uhlig T, Watt I, Pascual E. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011 Apr;70(4):563-70. [PubMed: 21216817]
15.Schlee S, Bollheimer LC, Bertsch T, Sieber CC, Härle P. Crystal arthritides – gout and calcium pyrophosphate arthritis : Part 2: clinical features, diagnosis and differential diagnostics. Z Gerontol Geriatr. 2018 Jul;51(5):579-584. [PubMed: 28233118]
16.Gersing AS, Schwaiger BJ, Heilmeier U, Joseph GB, Facchetti L, Kretzschmar M, Lynch JA, McCulloch CE, Nevitt MC, Steinbach LS, Link TM. Evaluation of Chondrocalcinosis and Associated Knee Joint Degeneration Using MR Imaging: Data from the Osteoarthritis Initiative. Eur Radiol. 2017 Jun;27(6):2497-2506. [PubMed: 27704199]
17.Sidari A, Hill E. Diagnosis and Treatment of Gout and Pseudogout for Everyday Practice. Prim Care. 2018 Jun;45(2):213-236. [PubMed: 29759121]
18.Shen G, Su M, Liu B, Kuang A. A Case of Tophaceous Pseudogout on 18F-FDG PET/CT Imaging. Clin Nucl Med. 2019 Feb;44(2):e98-e100. [PubMed: 30325826]
19.Muthukumar N, Karuppaswamy U. Tumoral calcium pyrophosphate dihydrate deposition disease of the ligamentum flavum. Neurosurgery. 2003 Jul;53(1):103-8; discussion 108-9. [PubMed: 12823879]
20.Yayama T, Kobayashi S, Sato R, Uchida K, Kokubo Y, Nakajima H, Takamura T, Mwaka E, Orwotho N, Baba H. Calcium pyrophosphate crystal deposition in the ligamentum flavum of degenerated lumbar spine: histopathological and immunohistological findings. Clin Rheumatol. 2008 May;27(5):597-604. [PubMed: 17934688]
21.Abhishek A, Doherty M. Update on calcium pyrophosphate deposition. Clin Exp Rheumatol. 2016 Jul-Aug;34(4 Suppl 98):32-8. [PubMed: 27586801]
22.Stensby JD, Lawrence DA, Patrie JT, Gaskin CM. Prevalence of asymptomatic chondrocalcinosis in the pelvis. Skeletal Radiol. 2016 Jul;45(7):949-54. [PubMed: 27037810]
23.Felson DT, Anderson JJ, Naimark A, Kannel W, Meenan RF. The prevalence of chondrocalcinosis in the elderly and its association with knee osteoarthritis: the Framingham Study. J Rheumatol. 1989 Sep;16(9):1241-5. [PubMed: 2810282]
24.Moshrif A, Laredo JD, Bassiouni H, Abdelkareem M, Richette P, Rigon MR, Bardin T. Spinal involvement with calcium pyrophosphate deposition disease in an academic rheumatology center: A series of 37 patients. Semin Arthritis Rheum. 2019 Jun;48(6):1113-1126. [PubMed: 30415946]
25.Grassi W, Okano T, Filippucci E. Use of ultrasound for diagnosis and monitoring of outcomes in crystal arthropathies. Curr Opin Rheumatol. 2015 Mar;27(2):147-55. [PubMed: 25633243]
26.Filippucci E, Di Geso L, Girolimetti R, Grassi W. Ultrasound in crystal-related arthritis. Clin Exp Rheumatol. 2014 Jan-Feb;32(1 Suppl 80):S42-7. [PubMed: 24528621]
Disclosures:
Edgar Zamora declares no relevant financial relationships with ineligible companies.
Roopa Naik declares no relevant financial relationships with ineligible companies.
